Clinical Trial Update: Bevacizumab and Trabectedin +/- Carboplatin in Advanced Ovarian Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial assessing bevacizumab and trabectedin with or without carboplatin in recurrent ovarian epithelial cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epithelial Ovarian Cancer
• Ovarian Cancer
• Ovarian Epithelial Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• CARBOPLATIN (Carboplatin)
• Trabectedin (trabectedin)

Snippet

Sponsor: Mario Negri Institute for Pharmacological Research | Conditions: Ovarian Epithelial Cancer Recurrent | Phase 2 | Status: COMPLETED